Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.
about
Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patientsThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsNicotinamide-rich diet protects the heart against ischaemia-reperfusion in mice: a crucial role for cardiac SUR2AAtherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment.Nicotinic acid activates the capsaicin receptor TRPV1: Potential mechanism for cutaneous flushing.Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parametersHigh dietary niacin may increase prostaglandin formation but does not increase tumor formation in ApcMin/+ mice.Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials.Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.Nicotinic acid is a common regulator of heat-sensing TRPV1-4 ion channelsNew compounds able to control hepatic cholesterol metabolism: Is it possible to avoid statin treatment in aged people?Blood lipids and stroke: what more can we do besides reducing low-density lipoprotein cholesterol?Nicotinamide phosphoribosyltransferase (Nampt) affects the lineage fate determination of mesenchymal stem cells: a possible cause for reduced osteogenesis and increased adipogenesis in older individuals.Themed section: Advances in nutritional pharmacology. Editorial.Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients.Niacin as potential treatment for dyslipidemia and hyperphosphatemia associated with chronic renal failure: the need for clinical trials.GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus.The hypotriglyceridemic effect of biotin supplementation involves increased levels of cGMP and AMPK activation.Niacin and olive oil promote skewing to the M2 phenotype in bone marrow-derived macrophages of mice with metabolic syndrome.
P2860
Q26996051-06AA11B8-8478-424C-85DC-B88F6BC2EAFEQ30486707-A476A5AA-5642-49C2-84B6-FCC59474A426Q33524963-BCC18C96-E802-40A2-B4B6-C51C1588C132Q33776194-9BA19190-8974-4512-AFD5-AD3EF4746B26Q33776230-2E155508-FD1C-44DB-A785-4EFD2A1C5976Q33778078-4FC51439-3183-45F1-B9DF-901ED5664376Q35440499-B01C6340-6F78-4051-9C68-0E27C7645AEFQ35575144-22E366F3-BD5E-4A25-B438-C9B5449FCB17Q36088110-A81E2E7D-8487-4094-983A-F10ED9073D96Q36419283-1702F1DB-5466-4140-836E-F126AD85FB2CQ36972642-892FA871-5E59-4D7C-A95B-98E7FCE74229Q37429025-7B132AD1-6EF1-4D18-A911-B9D6469AEE4CQ37894582-5B908304-3199-4FDE-9F32-9181273A0398Q39496015-0F1D3FB0-C33B-407B-AB32-FA7B5057CAABQ42577476-F163B064-B44C-4524-8029-98B3E7C2BFDEQ42953398-B832358A-5FED-4EFD-8CC2-8659C98110A4Q43058587-17B6CD07-F76E-4EC6-870B-968A459A3EB3Q44066995-EFE5BE30-B94D-4037-9981-1E125C22C83BQ47374423-AC4B2B16-B584-4372-B02F-241D2B581A5CQ54357408-47101ACE-EF7A-4C0D-BE30-C84C328E53B2
P2860
Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.
@en
Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.
@nl
type
label
Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.
@en
Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.
@nl
prefLabel
Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.
@en
Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.
@nl
P2860
P1476
Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.
@en
P2860
P304
P356
10.1111/J.1476-5381.2009.00349.X
P407
P50
P577
2009-07-20T00:00:00Z